title: The development of PARP inhibitors in ovarian cancer: from bench to bedside.
abstract: The nuclear enzyme poly (ADP-ribose) polymerase (PARP) represents an important novel target in the treatment of ovarian cancer. This article charts over 50 years of research from the discovery of the first PARP enzyme in 1963, to the approval and licensing in 2015 of the first PARP inhibitor, olaparib (Lynparza), in the treatment of BRCA-mutated ovarian cancer.
authors.affiliation: Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.|Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK.
authors.forename: Yvette
authors.initials: Y
authors.lastname: Drew
mesh_terms: D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D000067856:Poly(ADP-ribose) Polymerase Inhibitors